You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

Learning hub

Scientific and Clinical Updates

Learn About Scientific and Clinical Updates Across Type 2 Inflammatory Conditions

Explore a comprehensive collection of educational resources designed to enhance your understanding and management of various type 2 inflammatory diseases.

Each learning hub page functions as a centralized repository of information for a specific therapeutic area, meticulously organized by key topics relevant to your clinical practice, such as pathophysiology, burden of disease, and disease management strategies. Delve into the underlying mechanisms, assess the clinical impact, and review current best practices for patient care.

To support learning and self-assessment, each hub includes a quiz section, allowing you to gauge your understanding of the key concepts and principles.

Begin by selecting your area of interest below.

Learning Hub

EoE Learning Hub

Welcome to the EoE learning hub focused on key scientific education on eosinophilic esophagitis, featuring ADVENT resources.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: FinlandChange country/region